替吉奥联合每周紫杉醇脂质体一线治疗晚期胃癌的临床分析.pdfVIP

英文摘要 替吉奥联合每周紫杉醇脂质体一线治疗晚期胃癌的临床研究 Effect of S-1 Combined with the Weekly Administration of Liposome–Paclitaxel as first-line chemotherapy on Advanced Gastric Cancer Abstract Objective: This study is aimed to assess the efficacy and toxicity of S-1 and weekly liposome – paclitaxel combination therapy as first-line treatment for advanced gastric cancer. Methods: The chemotherapy regime was S-1 60 mg (body surface area 1.5) or 50 mg (1.25 , body surface area , 1.5) twice a day on days 1 – 28, combined with 80 mg/m2 liposome – paclitaxel given on days 1, 8, 15 and 22, 6 weeks as one cycle. Treatment was continued until progressive disease or intolerable toxicity occurred. The response rate, progression-free survival (PFS), overall survival (OS) and toxicity were evaluated after 2 cycles. Results: A total of 26 patients were enrolled, and the median age was 53 years (range ＝28 –70 years; 16 males and 10 females). The response rate and disease control rate were 34.6% （9/26 ）and 88.5% (23/26), respectively. The median PFS was 6.0 months, and the median OS was 10.0 months. The main treatment related toxicities were hematological toxicity，fatigue，and gastrointestinal reaction. Grade III～IV toxicity included neutropenia (7.7%)，nausea and vomiting(3.9%)and diarrhea(3.9%). Conclusions: The weekly administration of a combined regimen of liposome– paclitaxel plus S-1 is effective and has a favorable toxicity profile as first-line treatment for advanced gastric cancer. Keywords: advanced gastric cancer; S-1; liposome – paclitaxel; efficacy; toxicity Written by : Zhu Yajun Supervised by: Zhuang Zhixiang